Dragana Milojković

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 770 citations · Full text

Medicine, Cardiology, Oncology +16

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad et al. · Journal of Clinical Oncology · 2008 · 556 citations

Medicine, Hematology, Pharmacology +8

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 493 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13